Vaccines remain one of the most effective public health interventions, preventing an estimated 3.5 to 5 million deaths annually worldwide. Reflecting their growing importance, approximately 7.2 billion vaccine doses were supplied globally in 2024. As vaccine technologies continue to evolve, comprehensive preclinical safety assessment plays a critical role in evaluating safety, characterizing immune responses, and generating the data required to support regulatory submissions and progression into clinical trials.
Vaccines are administered to healthy individuals, including infants, children, adults, and potentially vulnerable populations. Consequently, regulatory agencies require comprehensive nonclinical data to ensure that potential risks are adequately characterized before clinical evaluation.
Preclinical safety assessment combines in vitro and in vivo studies to evaluate toxicity, immunogenicity, dose-response relationships, and product performance. The resulting data support critical regulatory submissions such as Biologics License Application (BLA) applications and Clinical Trial Applications (CTA). Additional studies may also be required following significant manufacturing or formulation changes, or when safety concerns emerge during clinical development.
Global regulatory agencies, including the World Health Organization (WHO), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA), require robust nonclinical safety data to support vaccine development. Regulatory expectations are further aligned through international harmonization initiatives such as the International Council for Harmonisation (ICH) and the International Coalition of Medicines Regulatory Authorities (ICMRA), which support greater harmonization of global regulatory requirements.
To ensure data quality, integrity, and traceability, pivotal nonclinical safety studies supporting regulatory submissions are generally conducted in compliance with Good Laboratory Practice (GLP) principles.
Immunogenicity studies provide proof-of-concept data and help characterize the immune response generated by a vaccine candidate. Animal models are typically immunized using the intended clinical regimen, and both humoral and cellular immune responses are evaluated.
Key parameters assessed include:
Basic toxicology studies evaluate the potential toxic effects of a vaccine with respect to dose, route of administration, frequency, and duration of exposure. These studies help identify target-organ toxicity and determine whether any observed adverse effects are reversible.
Evaluations typically include clinical observations, body weight and food consumption measurements, hematology, clinical chemistry, coagulation parameters where appropriate, urinalysis, serum immunoglobulin assessments, and detailed histopathological examination of tissues and  organs.
Depending on the vaccine and intended patient population, regulators require additional investigations.
Developmental and reproductive toxicity studies are necessary when vaccines are intended for pregnant women or women of childbearing potential. These studies assess parameters such as fetal viability, resorptions, abortions, fetal body weights, and fetal morphology.
Genotoxicity and carcinogenicity studies may be required for novel adjuvants, excipients, or additives. Safety pharmacology assessments may also be performed to evaluate potential effects on critical physiological systems, including cardiovascular, respiratory, and central nervous system functions.
Certain vaccine platforms require additional evaluations beyond standard vaccine safety studies:
Selecting an appropriate animal model is a critical aspect of vaccine safety assessment. Regulatory agencies recommend using biologically relevant species that provide adequate exposure and meaningful interpretation of safety findings. In some cases, multiple animal models may be required to fully characterize potential toxicities.
Alternative routes of administration, such as intranasal delivery, may also influence vaccine potency, immunogenicity, tolerability, and long-term safety. As a result, route-specific nonclinical safety evaluations are often necessary to support clinical development.
The increasing complexity of vaccine technologies presents several challenges during nonclinical development. Organizations must carefully select relevant animal models, evaluate novel adjuvants and delivery systems, balance immunogenicity with reactogenicity, generate reproducible bioanalytical data, and meet evolving global regulatory requirements.
Emerging platforms such as mRNA and viral vector vaccines may require additional biodistribution, persistence, and platform-specific safety assessments. Addressing these challenges through well-designed preclinical studies can help minimize development risks and facilitate regulatory review.
Successfully navigating vaccine development requires expertise across toxicology, immunology, pathology, bio analytics, and regulatory science. An experienced Contract Research Organization (CRO) can help optimize study design, generate high-quality regulatory-compliant data, and support efficient progression from preclinical development into clinical trials.
Key capabilities to consider when selecting a vaccine development partner include:
Adgyl Lifesciences supports vaccine developers through an integrated preclinical safety assessment platform designed to meet global regulatory expectations. The organization operates a 125,000 sq. ft. safety assessment facility with extensive vivarium infrastructure, multiple laboratory animal species, and integrated pathology and toxicology capabilities.
With 30+ years of GLP experience, We have supported 35 integrated drug discovery programs, 100 IND applications, 25,000+ regulatory studies, and 50+ safety assessment programs, while contributing to submissions across major global regulatory agencies. Our facility is India’s first GLP test facility, OECD-certified, USFDA-audited for GLP, and AAALAC-certified. We combine scientific expertise with globally recognized quality standards, including OLAW registration.
Adgyl Lifesciences has experience supporting the safety assessment of multiple vaccine platforms, including live attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid, recombinant vector vaccines, and conjugate vaccines.
The organization has supported the safety evaluation of a diverse range of vaccine candidates and biologics, including:
Adgyl Lifesciences conducts a broad range of GLP-compliant studies to support vaccine development, including:
The organization also has experience evaluating vaccines administered through intramuscular, subcutaneous, and intranasal routes.
Adgyl Lifesciences offers a broad range of in vitro and bioanalytical assays to support vaccine characterization, immunogenicity assessment, and safety evaluation, including:
Potency and Functional Assays
Immunogenicity and Serology
Identity and Phenotypic Characterization
Impurity and Immunogenicity Testing
Additional Infrastructure Capabilities
Adgyl Lifesciences maintains extensive historical datasets from repeat-dose, reproductive, and developmental toxicology studies. Evaluate endpoints include body weight, food consumption, clinical signs, hematology, clinical chemistry, coagulation, urinalysis, biomarkers, cytokines, histopathology, organ weights, fertility indices, sperm parameters, fetal weights, and developmental abnormalities.
To ensure data integrity and regulatory compliance, Adgyl utilizes integrated electronic data capture platforms, including LIMS and Provantis-enabled systems. The organization is SEND-ready and has successfully completed 363 SEND-format submissions supporting global regulatory filings.
Preclinical safety assessment is a critical step in advancing vaccine candidates from discovery to clinical development. Generating high-quality preclinical data requires scientifically sound study designs, comprehensive immunogenicity and toxicology evaluations, robust data management, and adherence to global regulatory standards.
With 30+ years of GLP experience, extensive vaccine safety assessment expertise, integrated pathology and toxicology capabilities, multiple animal models, SEND-ready data systems, and a proven track record supporting global regulatory submissions, Adgyl Lifesciences is well positioned to support vaccine developers throughout the preclinical development journey.
Discuss your vaccine platform, study requirements, and regulatory objectives with our preclinical vaccine safety experts
Email : enquiry@adgyllifesciences.com
Contact Us: +918066552700